Risk-based and diagnostics-linked personalized medicine for cancer

Authors: Srivastava, Sudhir; Wagner, Paul D

Source: Personalized Medicine, Volume 4, Number 1, February 2007 , pp. 33-43(11)

Publisher: Future Medicine

Buy & download fulltext article:

OR

Price: $73.00 plus tax (Refund Policy)

Abstract:

Personalized medicine is gaining momentum in healthcare by allowing physicians to determine an individual's predisposition to different diseases and to better diagnose and treat those diseases. Personalized medicine is frequently described as the right drug for the right patient at the right time; that is, a physician will prescribe treatment based on the individual characteristics of each patient such that the patient is likely to respond to a particular treatment with minimal adverse events. The heterogeneity of cancer makes the implementation of personalized medicine a necessity.

Keywords: biomarkers; cancer; oncogenes; raloxifene; risk assessment; tamoxifen; tumor suppressor genes

Document Type: Research article

DOI: http://dx.doi.org/10.2217/17410541.4.1.33

Affiliations: 1: 1Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, 6130 Executive Boulevard, Suite 3142, Rockville, MD 20892, USA., Email: ss1a@nih.gov

Publication date: 2007-02-01

More about this publication?
Related content

Tools

Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content

Text size:

A | A | A | A
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages. print icon Print this page